Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.51 |
| ▸ | CDK2 | P24941 | 1/20 | 0.51 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | FBP1 | P09467 | 9/20 | 0.49 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | FPR2 | P25090 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13039 | 0.83 | FPR3 (0.54) | SMN1; SMN2MAPK10RAB9ACCNE1CDK2 | |
| SCHEMBL1749806 | 0.81 | SMN1; SMN2 (0.59) | SMN1; SMN2MAPK10RAB9ACCNE1CDK2 | |
| Ammonia Solution, Strong SCHEMBL27883952 | 0.80 | SMN1; SMN2 (0.58) | SMN1; SMN2MAPK10RAB9ACCNE1CDK2 | |
| SCHEMBL15943684 | 0.80 | RAB9A (0.57) | SMN1; SMN2MAPK10RAB9ANPC1PKM | |
| SCHEMBL6729 | 0.79 | CCNE1 (0.59) | SMN1; SMN2MAPK10RAB9ACCNE1CDK2 | |
| SCHEMBL29353713 | 0.79 | SMN1; SMN2 (0.64) | SMN1; SMN2MAPK10RAB9ANPC1MAPK1 | |
| SCHEMBL28830687 | 0.79 | FPR3 (0.47) | SMN1; SMN2MAPK10RAB9ACCNE1CDK2 | |
| SCHEMBL14476229 | 0.78 | SMN1; SMN2 (0.55) | SMN1; SMN2MAPK10RAB9ACCNE1CDK2 | |
| SCHEMBL13499905 | 0.78 | CCNE1 (0.65) | SMN1; SMN2MAPK10RAB9ACCNE1CDK2 | |
| SCHEMBL17353987 | 0.77 | SMN1; SMN2 (0.72) | SMN1; SMN2MAPK10RAB9ACCNE1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7514567-B2 | Oxazolidinone nicotinic acetylcholine receptor agonists | ASTRAZENECA AB (SE) | 2009-04-07 | — | — | US | disclosed |
| US-7514567-B2 | Oxazolidinone nicotinic acetylcholine receptor agonists | ASTRAZENECA AB (SE) | 2009-04-07 | — | — | US | disclosed |
| US-7514567-B2 | Oxazolidinone nicotinic acetylcholine receptor agonists | ASTRAZENECA AB (SE) | 2009-04-07 | — | — | US | disclosed |
| US-20080113983-A1 | Nicotinic Acetylcholine Receptor Ligands | ASTRAZENECA AB (SE) | 2008-05-15 | — | — | US | disclosed |
| US-20080113983-A1 | Nicotinic Acetylcholine Receptor Ligands | ASTRAZENECA AB (SE) | 2008-05-15 | — | — | US | disclosed |
| US-20080113983-A1 | Nicotinic Acetylcholine Receptor Ligands | ASTRAZENECA AB (SE) | 2008-05-15 | — | — | US | disclosed |
| US-20060154945-A1 | Spiro '1-azabicyclo' 2.2.2! octan-3,5'-oxazolidin - 2'-one! derivatives with affinity to the alpha7 nicotinic acetylcholine receptor | ASTRAZENECA AB (SE) | 2006-07-13 | — | — | US | disclosed |
| EP-1654264-A1 | SPIRO [1-AZABICYCLO [2.2.2]OCTANE-3,5'-OXAZOLIDIN-2'-ONE] DERIVATIVES WITH AFFINITY TO THE ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR | AstraZeneca AB (SE) | 2006-05-10 | — | — | EP | disclosed |
| WO-2005005435-A1 | SPIRO ′1-AZABICYCLO ′2.2.2!OCTAN-3,5′-OXAZOLIDIN -2′-ONE! DERIVATIVES WITH AFFINITY TO THE ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR | ASTRAZENECA AB (SE) | 2005-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060154945-A1 | Spiro '1-azabicyclo' 2.2.2! octan-3,5'-oxazolidin - 2'-one! derivatives with affinity to the alpha7 nicotinic acetylcholine receptor | CHRNA1, CHRNA7, ADRA1D | SMN1; SMN2 1710/4885MAPK10 3451/4885RAB9A 2444/4885 |
| US-20080113983-A1 | Nicotinic Acetylcholine Receptor Ligands | CHRNA1, CHRNA2, CHRNB1 | SMN1; SMN2 1210/4885MAPK10 3272/4885RAB9A 1451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.